

## Brynovin<sup>™</sup> (sitagliptin) – New drug approval

- On January 16, 2025, the FDA approved Azurity Pharmaceuticals' <u>Brynovin (sitagliptin)</u> oral solution, as an adjunct to diet and exercise to **improve glycemic control in adults with type 2** diabetes mellitus.
  - Brynovin is not recommended in patients with type 1 diabetes.
  - Brynovin has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using Brynovin.
- Brynovin is the **first oral solution formulation of sitagliptin**. Sitagliptin is also available generically as an oral tablet.
- The effectiveness of Brynovin has been established for glycemic control in patients with type 2 diabetes mellitus based on adequate and well-controlled trials of sitagliptin tablets.
- Warnings and precautions for Brynovin include pancreatitis; heart failure; acute renal failure; hypoglycemia with concomitant use with insulin or insulin secretagogues; hypersensitivity reactions; severe and disabling arthralgia; and bullous pemphigoid.
- The most common adverse reactions (≥ 5%) with Brynovin use are upper respiratory tract infection, nasopharyngitis and headache. In the add-on to sulfonylurea and add-on to insulin trials, hypoglycemia was also more commonly reported in patients treated with sitagliptin compared to placebo.
- The recommended dose of Brynovin is 100 mg (4 mL) taken orally once daily.
- Azurity Pharmaceuticals' launch plans for Brynovin are pending. Brynovin will be available as a 25 mg/mL oral solution.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews<sup>®</sup> is published by the Optum Rx Clinical Services Department.